产品
编 号：F370968
分子式：C15H10Cl2N2O2
分子量：321.16
分子式：C15H10Cl2N2O2
分子量：321.16
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
询价
询价
5mg
412
In-stock
10mg
733
In-stock
50mg
2080
In-stock
100mg
2971
In-stock
结构图
CAS No: 50264-69-2
产品详情
生物活性：
Lonidamine (AF-1890) is a hexokinase and mitochondrial pyruvate carrier inhibitor (Ki: 2.5 μM). Lonidamine also inhibits aerobic glycolysis in cancer cells. Lonidamine can be used in the research of mitochondrial metabolism and inflammation, such as pulmonary fibrosis.
体内研究：
Lonidamine (oral administration, 10-100 mg/kg/day, d10 to d20) improves lung function by inhibiting hexokinase 2 (HK2) activity in BLM-induced pulmonary fibrosis murine model.Animal Model:Lonidamine (oral administration, 10-100 mg/kg/day, d10 to d20) improves lung function by inhibiting hexokinase 2 (HK2) activity in BLM-induced pulmonary fibrosis murine model.
Dosage:10, 30, 100 mg/kg/day
Administration:Oral administration, daily, d10 to d20 after BLM treatment.
Result:Partially or completely reversed the increases in HK2 and lactate induced by BLM and reduced the expression of 10 profibrotic mediators.
体外研究：
Lonidamine (100 μM, 24 h) inhibits TGF-β-stimulated lactate production and oxygen consumption rate in AKR-2B and TIG-1 cells.Lonidamine (100 μM, 24/48 h) inhibits H2030BrM3 and A549 cell proliferation.Lonidamine (100-200 μM, 24 h) inhibits H2030BrM3 and A549 cell invasion.Lonidamine (100-1000 μM, 24 h) inhibits mitochondrial complex I and II activities.Lonidamine (200 μM, 24 h) increases ROS generation in H2030BrM3 lung cancer cells.
Lonidamine (AF-1890) is a hexokinase and mitochondrial pyruvate carrier inhibitor (Ki: 2.5 μM). Lonidamine also inhibits aerobic glycolysis in cancer cells. Lonidamine can be used in the research of mitochondrial metabolism and inflammation, such as pulmonary fibrosis.
体内研究：
Lonidamine (oral administration, 10-100 mg/kg/day, d10 to d20) improves lung function by inhibiting hexokinase 2 (HK2) activity in BLM-induced pulmonary fibrosis murine model.Animal Model:Lonidamine (oral administration, 10-100 mg/kg/day, d10 to d20) improves lung function by inhibiting hexokinase 2 (HK2) activity in BLM-induced pulmonary fibrosis murine model.
Dosage:10, 30, 100 mg/kg/day
Administration:Oral administration, daily, d10 to d20 after BLM treatment.
Result:Partially or completely reversed the increases in HK2 and lactate induced by BLM and reduced the expression of 10 profibrotic mediators.
体外研究：
Lonidamine (100 μM, 24 h) inhibits TGF-β-stimulated lactate production and oxygen consumption rate in AKR-2B and TIG-1 cells.Lonidamine (100 μM, 24/48 h) inhibits H2030BrM3 and A549 cell proliferation.Lonidamine (100-200 μM, 24 h) inhibits H2030BrM3 and A549 cell invasion.Lonidamine (100-1000 μM, 24 h) inhibits mitochondrial complex I and II activities.Lonidamine (200 μM, 24 h) increases ROS generation in H2030BrM3 lung cancer cells.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备